Melanoma: The intersection of molecular targeted therapy and immune checkpoint inhibition

Peter Kar Han Lau, Paolo A. Ascierto, Grant McArthur

Research output: Contribution to journalArticlepeer-review

Abstract

Melanoma is at the forefront of development of systemic therapeutics with both molecular targeted therapies and immune checkpoint inhibitors as cornerstones of treatment. Although responses to molecularly targeted therapy is largely from blockade of oncogenic pathways, evidence is emerging of the immunomodulatory effects from BRAF inhibition. Additionally programmed-death-1 (PD-1) inhibitors have revolutionized the treatment of melanoma and are set to pave future improvements in other solid tumors. Combinations of PD-1 inhibitors with novel immune checkpoints or with molecularly targeted therapies are under investigation and may improve on the considerable progress made.

Original languageEnglish
Pages (from-to)30-38
Number of pages9
JournalCurrent Opinion in Immunology
Volume39
DOIs
Publication statusPublished - Apr 1 2016

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Melanoma: The intersection of molecular targeted therapy and immune checkpoint inhibition'. Together they form a unique fingerprint.

Cite this